Patent · US Active

3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament

US12115157B2 · kind B2 · utility

0Cited by

1References

15Claims

0Family size

Assignees

Boehringer Ingelheim International GmbH · DE
Arena Pharmaceuticals, Inc. · US

Inventors

Kai Gerlach · Biberach, DE
Daniela Berta · Milano, IT
Marco Ferrara · San Donato Milanese, IT
Kirsten Gutsche · Laupheim, DE
Ursula Mueller-Vieira · Ingelheim am Rhein, DE
Scott Hobson · Mittelbiberach, DE
Frank Runge · Biberach an der Riß, DE
Graeme Semple · Mölndal, SE
Viktor Vintonyak · Warthausen, DE
Yifeng Xiong · San Diego, US

Key dates

Filing date	Sep 9, 2022
Grant date	Oct 15, 2024
Priority date	—
Expiry date	Oct 26, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/09
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases.In addition, the invention relates to the 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) for use as a medicament, pharmaceutical compositions comprising at least a compound of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.